Literature DB >> 9781730

Neutrophil accumulation is reduced during partial liquid ventilation.

D M Colton1, G O Till, K J Johnson, S B Dean, R H Bartlett, R B Hirschl.   

Abstract

OBJECTIVE: This study evaluates the ability of perflubron to inhibit pulmonary neutrophil accumulation during partial liquid ventilation (PLV) in the setting of acute lung injury.
DESIGN: Randomized, controlled, nonblinded study.
SETTING: Research laboratory at a university.
SUBJECTS: Male, Sprague-Dawley rats (n = 120, 506 +/- 42 g).
INTERVENTIONS: Animals were divided into eight groups (n = 15 in each group, of which n = 12 for myeloperoxidase content and n = 3 for histologic neutrophil counting): a) GV-CVF group, animals received gas ventilation (GV) with the induction of lung injury using cobra venom factor (CVF); b) PLV-CVF group, animals received partial liquid ventilation before the induction of lung injury; c) PEEP-CVF group, animals received positive end-expiratory pressure (PEEP) before the administration of cobra venom factor; d) CVF-PLV group, animals received partial liquid ventilation after cobra venom factor; e) CVF-PEEP group, animals received PEEP after cobra venom factor; f) PLV only group, animals received partial liquid ventilation only; g) GV only group, animals received gas ventilation only; and h) NVSBA group, nonventilated spontaneous breathing animals.
MEASUREMENTS AND MAIN RESULTS: After the experimental period, total lung myeloperoxidase content was significantly decreased in the PLV-CVF (0.29 +/- 0.08, p = .02) and PEEP-CVF (0.34 +/- 0.04, p = .01) groups when compared with the GV-CVF group (0.62 +/- 0.07). When compared with the GV-CVF group, a trend toward a reduction in myeloperoxidase was observed in the CVF-PLV (0.42 +/- 0.05, p = .07) and the CVF-PEEP (0.39 +/- 0.06, p = .07) groups. When compared with the cobra venom factor only group (GV-CVF 47 +/- 2 neutrophils/high-power field), reductions in neutrophil count were observed in all groups (neutrophils/high-power field): PLV-CVF (20 +/- 2, p = .009); PEEP-CVF (24 +/- 1, p = .01); CVF-PLV (30 +/- 2, p = .03); and CVF-PEEP (37 +/- 1, p = .04).
CONCLUSION: These data suggest that both partial liquid ventilation and PEEP result in a reduction in neutrophil accumulation in the setting of acute lung injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781730     DOI: 10.1097/00003246-199810000-00028

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

1.  High-frequency oscillatory ventilation combined with partial liquid ventilation in experimental lung injury: effects on lung cell apoptosis.

Authors:  Huimin Zuo; Linxiang Zeng; Guanghua Guo; Huihong Zeng
Journal:  Wien Klin Wochenschr       Date:  2015-04-03       Impact factor: 1.704

2.  Hydrochloric acid-induced lung injury: effects of early partial liquid ventilation on survival rate, gas exchange, and pulmonary neutrophil accumulation.

Authors:  Michael A Pakulla; David Seidel; Detlef Obal; Stephan A Loer
Journal:  Intensive Care Med       Date:  2004-09-21       Impact factor: 17.440

3.  Effect of partial liquid ventilation on bacterial clearance during Pseudomonas aeruginosa-induced lung injury in rats.

Authors:  Saïda Rezaiguia-Delclaux; Kun Yang; François Stephan; François Lemaire; Michel Meignan; Alain Harf; Philippe Duvaldestin; Christophe Delclaux
Journal:  Intensive Care Med       Date:  2003-05-24       Impact factor: 17.440

4.  [Preserved spontaneous breathing during partial liquid ventilation. Results of experimental animal studies and their clinical implications].

Authors:  H D Hummler; F Pohlandt; A Schulze
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

5.  Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Authors:  Marla R Wolfson; Perenlei Enkhbaatar; Satoshi Fukuda; Christina L Nelson; Robert O Williams; Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Gennaro Calendo; Andrey A Komissarov; Galina Florova; Krishna Sarva; Steven I Idell; Thomas H Shaffer
Journal:  Clin Transl Med       Date:  2020-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.